Charles J. Ryan
A5012804612- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Prostate Cancer Diagnosis and Treatment
- Hormonal and reproductive studies
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Estrogen and related hormone effects
- Multiple Myeloma Research and Treatments
- Science, Research, and Medicine
- Genetic factors in colorectal cancer
- Renal cell carcinoma treatment
- Neuroendocrine Tumor Research Advances
- Immunotherapy and Immune Responses
- Lung Cancer Research Studies
- Cancer, Hypoxia, and Metabolism
- Neuroblastoma Research and Treatments
- Sexual Differentiation and Disorders
- Bone health and treatments
- Peptidase Inhibition and Analysis
- Advanced Breast Cancer Therapies
- Radiomics and Machine Learning in Medical Imaging
- CAR-T cell therapy research
University of Minnesota
2017-2025
Memorial Sloan Kettering Cancer Center
2004-2025
Prostate Cancer Foundation
2022-2024
University of Michigan
2007-2024
University of Minnesota Medical Center
2019-2024
Twin Cities Orthopedics
2019-2024
University of Minnesota System
2022-2023
University of California, San Francisco
2012-2022
Institute of Oncology Research
2022
Tel Aviv University
2022
Biosynthesis of extragonadal androgen may contribute to the progression castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor biosynthesis, prolongs overall survival among patients with metastatic cancer who have received chemotherapy.We randomly assigned, in a 2:1 ratio, 1195 had previously docetaxel receive 5 mg prednisone twice daily either 1000 acetate (797 patients) or placebo (398 patients). The primary end point was survival. secondary points...
Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent who had not received previous
Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations succeed those from prior Prostate Cancer Clinical Trials Working Groups.An international expert committee of investigators (the Group 3 [PCWG3]) was reconvened expanded met in 2012-2015 formulate updated criteria on basis emerging data validation studies 2 recommendations.PCWG3...
Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) are not well characterized in the era modern androgen receptor (AR)-targeting therapy. We sought to characterize clinical genomic t-SCNC a multi-institutional prospective study. Methods Patients with progressive, metastatic castration-resistant (mCRPC) underwent tumor biopsy were followed for survival. Metastatic specimens independent, blinded pathology review along RNA/DNA...
In advanced prostate cancer (APC), successful drug development as well advances in imaging and molecular characterisation have resulted multiple areas where there is lack of evidence or low level evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some these topics. To present the report APCCC 2017. Ten important controversy APC management were identified: high-risk localised locally cancer; “oligometastatic” castration-naïve castration-resistant role APC;...
BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients mCRPC associated a BRCA alteration treated rucaparib 600 mg twice daily the phase II TRITON2 study.We enrolled who progressed after one two lines of next-generation androgen receptor-directed therapy taxane-based chemotherapy for mCRPC. Efficacy safety populations included...
Abstract Purpose: Clinical features characteristic of small-cell prostate carcinoma (SCPC), “anaplastic,” often emerge during the progression cancer. We sought to determine efficacy platinum-based chemotherapy in patients meeting at least one seven prospectively defined “anaplastic” clinical criteria, including exclusive visceral or predominantly lytic bone metastases, bulky tumor masses, low prostate-specific antigen levels relative burden, short response androgen deprivation therapy....
Persistence of ligand-mediated androgen receptor signaling has been documented in castration-resistant prostate cancers (CRPCs). Abiraterone acetate (AA) is a potent and selective inhibitor CYP17, which required for biosynthesis the testes, adrenal glands, tissue. This trial evaluated efficacy safety AA combination with prednisone to reduce symptoms secondary hyperaldosteronism that can occur monotherapy.Fifty-eight men progressive metastatic CRPC who experienced treatment failure...
The principal objective of this trial was to evaluate the antitumor activity abiraterone acetate, an oral, specific, irreversible inhibitor CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC).In multicenter, two-stage, phase II study, acetate 1,000 mg administered once daily continuously. primary end point achievement a prostate-specific antigen (PSA) decline > or = 50% at least seven 35 patients. Per attained design, more than could be enrolled if met....
Abiraterone acetate is a prodrug of abiraterone, selective inhibitor CYP17, the enzyme catalyst for two essential steps in androgen biosynthesis. In castration-resistant prostate cancers (CRPCs), extragonadal sources may sustain tumor growth despite castrate environment. This phase I dose-escalation study abiraterone evaluated safety, pharmacokinetics, and effects on steroidogenesis prostate-specific antigen (PSA) levels men with CPRC or without prior ketoconazole therapy.Thirty-three...
Innovations in treatments, imaging, and molecular characterisation advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some these topics supplement guidelines based on level 1 evidence.To present the results from APCCC 2019.Similar prior conferences, experts identified 10 important areas controversy regarding cancer:...
In a phase 2 study, rucaparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), showed high level activity in patients who had metastatic, castration-resistant prostate cancer associated with deleterious BRCA alteration. Data are needed to confirm and expand on the findings study.
There is a clear need for molecular subtyping approach in prostate cancer to identify clinically distinct subgroups that benefit from specific therapies.To subtypes based on luminal and basal lineage determine associations with clinical outcomes response treatment.The PAM50 classifier was used subtype 1567 retrospectively collected (median follow-up, 10 years) 2215 prospectively samples into luminal- basal-like subtypes.Metastasis, biochemical recurrence, overall survival, cancer–specific...
Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination (HRR) such as
Purpose Zoledronic acid decreases the risk for skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases but its role earlier natural history of disease is unknown. This phase III study evaluated efficacy safety treatment zoledronic castration-sensitive metastatic cancer. Patients Methods Men whose androgen-deprivation therapy was initiated within 6 months entry were randomly assigned a blinded 1:1 ratio to receive (4 mg intravenously every 4 weeks)...
Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary assessment. Critical needs include optimized multigene strategies that incorporate evolving genetic data, consistency in GT indications alternate evaluation models address the rising demand for services. A multidisciplinary consensus conference included experts, stakeholders, national organization leaders was convened response to current practice challenges develop implementation...
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations the clinical management of patients with clear cell and non-clear renal carcinoma. These Insights highlight recent updates/changes in these guidelines, updates include axitinib as first-line treatment option carcinoma, new data to support pazopanib subsequent therapy carcinoma after another tyrosine kinase inhibitor, guidelines follow-up
Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)-targeted nanoparticles is clinically effective, and the selective reduction PSMA-positive circulating tumor cells (CTCs) after treatment has implications for patient selection disease monitoring.To determine safety efficacy BIND-014, a PSMA-directed docetaxel-containing nanoparticle, in patients with metastatic castration-resistant prostate cancer (mCRPC).A multicenter open-label, phase 2 clinical trial...
The purpose of this work was to evaluate the effect androgen receptor (AR) inhibition on prostate-specific membrane antigen (PSMA) uptake imaged using <sup>68</sup>Ga-PSMA-11 PET in a mouse xenograft model and patient with castration-sensitive prostate cancer. <b>Methods:</b> We 3 groups 4 mice bearing LNCaP-AR xenografts before 7 d after treatment ARN-509, orchiectomy, or control vehicle. Additionally, we one cancer wk deprivation therapy (ADT). Uptake pre- posttreatment imaging measured...